Ebe ve Hemşirelerin Yenidoğandan Elde Edilen Kuru Kan Lekesi Örneklemesinin Preanalitik Aşamasındaki Uygulamalarının İncelenmesi

Yıl 2022, Cilt: 31 Sayı: 5, 371 - 379, 18.11.2022

Leyla Erdim , Neriman Zengin

https://doi.org/10.17942/sted.980918

Cited By: 1

Öz

En önemli koruyucu halk sağlık hizmetlerinden biri olan yenidoğanın kuru kan lekesi taramalarındaki amaç hasta bebeklerin erken tanınıp tedavilerine zamanında başlanması ve bu sayede daha iyi yaşam kalitesine sahip olmalarıdır. Tanının hızlı konulması için yenidoğanlardan elde edilen kuru kan lekesi örneklerinin kalitesi son derece önemlidir. Toplam test sürecindeki test isteğinin başlangıcından, alınan örneklerin laboratuvara teslimine kadar ki süreci tanımlayan preanalitik aşama, insan hatalarının büyük oranda yapıldığı ve hasta güvenliği açısından risk taşıyan önemli bir aşamadır. Yenidoğandan elde edilen kuru kan lekesi örneklemesinin preanalitik aşaması; hastadan kanın alınması, tarama kartına uygulanması, kartın kurutulması, saklanması ve laboratuvara gönderilmesi gibi birçok kritik işlem basamağından oluşur. Örnek toplamaktan sorumlu ebe ve hemşirelerin bu aşamadaki uygulamalarla ilgili önemli sorumlulukları vardır ve kilit konumdaki sağlık profesyonelidirler. Bu makalede ebe ve hemşirelerin yenidoğandan elde edilen kuru kan lekesi örneklemesinin preanalitik aşamasındaki sorumluluklarının incelemesi ve farkındalık düzeylerinin arttırılması amaçlanmıştır.

Anahtar Kelimeler

Preanalitik aşama, Yenidoğan, Örnek toplama, Ebelik, Hemşirelik

Destekleyen Kurum

YOK

Proje Numarası

YOK

Teşekkür

YOK

Kaynakça

• 1. Sahai I, Marsden D. Newborn screening. Crit Rev Cl Lab Sci 2009;46:55-82.
• 2. Bello S, Ferguson C, Wallis R. Improvements to the newborn bloodspot screening service are required to meet national standards. J Med Screen 2010;17:114-120.
• 3. Centers for Disease Control and Prevention. CDC Grand Rounds: Newborn screening and improved outcomes. MMWR Morb Mortal Wkly Rep 2012;61: 390-393.
• 4. Balk KG. Recommended newborn screening policy change for the NICU infant. Policy Polit Nurs Pract 2007;8:210-219.
• 5. AWHONN Position Statement. Newborn screening. JOGN 2016;45:135-136.
• 6. Etchegary H, Nicholls SG, Tessier L, Simmonds C, Potter BK, Brehaut JC, et al. Consent for newborn screening: Parents' and health-care professionals' experiences of consent in practice. Eur J Hum Genet 2016;24:1530-1534.
• 7. Joseph RA. Expanded newborn screening: Challenges to NICU nurses. Adv Neonatal Care 2017; 17:151-161.
• 8. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963; 32:338-343.
• 9. Ozben T. Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry. Clin Chem Lab Med 2013;51:157-176.
• 10. Tezel B, Dilli D, Bolat H, Sahman H, Ozbaş S, Acıcan D, et al. The development and organization of newborn screening programs in Turkey. J Clin Lab Anal 2014 28:63-69.
• 11. Türkiye Cumhuriyeti Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü Çocuk ve Ergen Sağlığı Daire Başkanlığı. Yenidoğan Metabolik ve Endokrin Hastalık Tarama Programı (NTP). Erişim tarihi: 23 Mart 2021, Erişim adresi: https://hsgm.saglik.gov.tr/tr/cocukergen-tp-liste/yenidogan_tarama_programi.html.
• 12. George RS, Moat SJ. Effect of dried blood spot quality on newborn screening analyte concentrations and recommendations for minimum acceptance criteria for sample analysis. Clin Chem 2016;62:466-475.
• 13. NSW and ACT Newborn Screening Programme, Sampling Information and Guidelines. Erişim tarihi: 17 Haziran 2020, Erişim adresi: https://www.schn.health.nsw.gov.au/files/attachments/newborn_screening_guidlines_2015.pdf.
• 14. Public Health Wales NHS Trust. Newborn Bloodspot Screening: Programme Handbook, A guide to newborn bloodspot screening (NBS) for health professionals in Wales. Erişim tarihi: 27 Aralık 2020, Erişim adresi: https://phw.nhs.wales/services-and-teams/screening/newborn-bloodspot-screening-wales/files/information-for-health-professionals-page/nbsw-handbook-08-02-2020-pdf/.
• 15. De Souza A, Wolan V, Battochio A, Christian S, Hume S, Johner G, et al. Newborn screening: current status in Alberta, Canada. Int J Neonatal Screen 2019;5: 37.
• 16. Da Rin G. Pre-analytical workstations: A tool for reducing laboratory errors. Clin Chim Acta 2009;404:68-74.
• 17. Guder WG. History of the preanalytical phase: A personal view. Biochem Med 2014; 24:25-30.
• 18. Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med 2006; 44:750-759.
• 19. Lippi G, Cadamuro J. Novel opportunities for improving the quality of preanalytical phase. A glimpse to the future? J Med Biochem 2017; 36:293-300.
• 20. Zakaria R, Allen KJ, Koplin JJ, Roche P, Greaves RF. Advantages and challenges of dried blood spot analysis by mass spectrometry across the total testing process. EJIFCC 2016 ;27:288-317.
• 21. Moat SJ, George RS, Carling RS. Use of dried blood spot specimens to monitor patients with inherited metabolic disorders. Int J Neonatal Screen 2020; 6:26.
• 22. Balashova EE, Trifonova OP, Maslov DL, Lokhov PG. Application of dried blood spot for analysis of low molecular weight fraction (metabolome) of blood. Health Prim Car 2018;2:1-11.
• 23. Public Health England. Guidelines for newborn blood spot sampling, Public Health England leads the NHS Screening Programmes. London: PHE publications gateway number:2015750; 2016.
• 24. Lawson AJ, Bernstone L, Hall SK. Newborn screening blood spot analysis in the UK: İnfluence of spot size, punch location and haematocrit. J Med Screen 2016;23: 7-16.
• 25. Tluczek A, Mischler EH, Bowers B, Peterson NM, Moris ME, Farrell PM, et al. Psychological impact of false-positive results when screening for Cystic Fibrosis. Pediatr Pulmonol Suppl 1991; 7: 29-37.
• 26. Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003;290:2564-2572.
• 27. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: The effect of a false-positive result. Pediatrics 2006; 117:1915-1921.
• 28. McDade TW, Williams S, Snodgrass JJ. What a drop can do: Dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography 2007; 44:899-925.
• 29. Tluczek A, Orland KM, Nick SW, Brown RL. Newborn screening: An appeal for improved parent education. J Perinat Neonatal Nurs 2009;23:326-334.
• 30. Wright SJ, Ulph F, Lavender T, Dharni N, Payne K. Understanding midwives’ preferences for providing information about newborn bloodspot screening. MDM Policy Pract 2018; 3:2381468317746170.
• 31. Winter T, Lange A, Hannemann A, Nauck M, Müller C. Contamination of dried blood spots-an underestimated risk in newborn screening. Clin Chem Lab Med 2018;56:278-284.
• 32. Cavanagh C, Coppinger C. Newborn blood spot sampling. Infant 2009;5: 168-171.
• 33. Krleza JL, Dorotic A, Grzunov A, Maradin M. Capillary blood sampling: National recommendations on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Biochem Med 2015; 25: 335-358.
• 34. Shah PS, Herbozo C, Aliwalas LL, Shah VS. Breastfeeding or breast milk for procedural pain in neonates. Cochrane Database Syst Rev 2012;12:Cd004950.
• 35. Morrow C, Hidinger A, Wilkinson-Faulk D. Reducing neonatal pain during routine heel lance procedures. MCN Am J Matern Child Nurs 2010;35: 346-354; quiz: 354-356.
• 36. Taking Blood from Infants for the HIV DNA PCR Test, Standard Operating Procedures. Erişim tarihi: 15 Ekim 2020, Erişim adresi: https://www.unicef.org/southafrica/media/2171/file/ZAF-taking-blood-from-infants-for-the-HIV-DNA-PCR-test-2009.pdf.
• 37. World Health Organization. WHO guidelines on drawing blood: Best practices in phlebotomy. The WHO Documenet Production Sevices, Geneva, Switzerland; 2010.
• 38. İçke S, Genç R. National newborn screening tests carried out with heel lance and their importance. J Pediatr Res 2017;4:186-190.
• 39. Ray R, Godwin Y, Shepherd A. Convective burn from use of hairdryer for heel warming prior to the heel prick test-a case report. BMC Pediatr 2011;11:30.
• 40. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr 2001;131:1631S-1636S.
• 41. World Health Organization. WHO Manual For HIV Drug Resistance Testing Using Dried Blood Spot Specimens. Geneva, Switzerland; 2012.
• 42. Mei JV, Zobel SD, Hall EM, De Jesús VR, Adam BW, Hannon WH. Performance properties of filter paper devices for whole blood collection. Bioanalysis 2010;2:1397-1403.
• 43. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü Çocuk ve Ergen Sağlığı Daire Başkanlığı. Temel Yenidoğan Bakımı. Erişim tarihi: 25 Kasım 2020, Erişim adresi:https://hsgm.saglik.gov.tr/depo/birimler/cocuk_ergen_db/dokumanlar/yayinlar/Kitaplar/1.2_revizyon_19.11.2019_Temel_Yenidogan_Bakimi_Kitabi_1.pdf.
• 44. Newborn Screening Ontario. Newborn Screening Manual, A Guide for Newborn Care Providers. Edition 2.1. Erişim tarihi: 25 Aralık 2020, Erişim adresi:https://www.newbornscreening.on.ca/sites/default/files/newborn_screening_manual_2018_-_web.pdf.
• 45. Nikolac N, Šupak-Smolčić V, Šimundić A-M, Ćelap I. Croatian society of medical biochemistry and laboratory medicine: National recommendations for venous blood sampling. Biochem Med 2013;23:242-254.
• 46. Grüner N, Stambouli O, Ross RS. Dried blood spots-preparing and processing for use in immunoassays and in molecular techniques. J Vis Exp 2015; 97: e52619.
• 47. Edelbroek PM, van der Heijden J, Stolk LML. Dried blood spot methods in therapeutic drug monitoring: Methods, assays, and pitfalls. Ther Drug Monit 2009; 31:327-336.
• 48. Lim MD. Dried blood spots for global health diagnostics and surveillance: Opportunities and challenges. Am J Trop Med Hyg 2018; 99:256-265.